Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

NCT06202313 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

128

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

BIOLOGICAL: Cadonilimab
DRUG: Eribulin

Sponsor

Shengjing Hospital